Leading drug producer Jiangsu Yingke Biopharmaceutical Co Ltd – located in the Taizhou Medical High-tech Zone, in Taizhou city, East China's Jiangsu province – recently held a groundbreaking ceremony for its Phase III expansion project.
Focusing on the high-end complex formulations field, on completion the plant will be engaged in the research and production of high-end generic drugs, innovative formulations and complex cream formulations.
Costing 300 million yuan ($41.31 million), the plant will build a special formulation production line, which is expected to have an annual output capacity of 40 million creams.
The groundbreaking of the Phase III plant marks the company's response to national policies and its determination to accelerate the layout and reform of the biopharma industry.
Founded in 2011, Jiangsu Yingke Biopharmaceutical Co is a modern high-tech biopharma group that integrates research and development, production and sales.
It is focused on the R&D of parenteral nutrition emulsions, anesthesia emulsions, liposomes and microspheres products.
The neat-looking exterior view of the premises of Jiangsu Yingke Biopharmaceutical Co Ltd. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]